531978 Sigma-AldrichATM Inhibitor, KU 60019 - CAS 925701-46-8 - Calbiochem
ATM kinase inhibitor, KU60019, is a cell permeable, potent inhibitor of ATM kinase inhibitor (IC₅₀ = 6.3 nM). Has 270 & 1600-fold higher selectivity over DNA-PK and ATR kinase.
More>> ATM kinase inhibitor, KU60019, is a cell permeable, potent inhibitor of ATM kinase inhibitor (IC₅₀ = 6.3 nM). Has 270 & 1600-fold higher selectivity over DNA-PK and ATR kinase. Less<<Synonyms: KU-60019, KU60019, Ataxia Telangiectasia Mutate Kinase Inhibitor
Recommended Products
Overview
| Replacement Information |
|---|
Key Spec Table
| CAS # | Empirical Formula |
|---|---|
| 925701-46-8 | C₃₀H₃₃N₃O₅S |
Pricing & Availability
| Catalogue Number | Availability | Packaging | Qty/Pack | Price | Quantity | |
|---|---|---|---|---|---|---|
| 5.31978.0001 |
|
Glass bottle | 10 mg |
|
— |
| References | |
|---|---|
| References | Biddlestone-Thorpe, L., et al. 2013. Clin. Cancer Res. 19, 3189. Golding, S., et al. 2009. Mol. Cancer Ther. 8, 2894. |
| Product Information | |
|---|---|
| CAS number | 925701-46-8 |
| Form | Light beige solid |
| Hill Formula | C₃₀H₃₃N₃O₅S |
| Chemical formula | C₃₀H₃₃N₃O₅S |
| Reversible | Y |
| Quality Level | MQ100 |
| Applications |
|---|
| Biological Information | |
|---|---|
| Primary Target | ATM |
| Primary Target IC<sub>50</sub> | 6.3 nM |
| Purity | ≥98% by HPLC |
| Physicochemical Information | |
|---|---|
| Cell permeable | Y |
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Product Usage Statements |
|---|
| Packaging Information | |
|---|---|
| Packaged under inert gas | Packaged under inert gas |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Catalogue Number | GTIN |
| 5.31978.0001 | 04055977287127 |
Documentation
ATM Inhibitor, KU 60019 - CAS 925701-46-8 - Calbiochem SDS
| Title |
|---|
References
| Reference overview |
|---|
| Biddlestone-Thorpe, L., et al. 2013. Clin. Cancer Res. 19, 3189. Golding, S., et al. 2009. Mol. Cancer Ther. 8, 2894. |



